217 related articles for article (PubMed ID: 28859471)
1. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
[TBL] [Abstract][Full Text] [Related]
2. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
Nasrazadani A; Marti JLG; Lathrop K; Restrepo A; Leu SY; Bhat G; Brufsky A
Breast Cancer Res Treat; 2024 May; 205(1):29-37. PubMed ID: 38261228
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.
Kim TY; Han HS; Lee KW; Zang DY; Rha SY; Park YI; Kim JS; Lee KH; Park SH; Song EK; Jung SA; Lee N; Kim YH; Cho JY; Bang YJ
Gastric Cancer; 2019 Nov; 22(6):1206-1214. PubMed ID: 30945121
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Yap TA; Vidal L; Adam J; Stephens P; Spicer J; Shaw H; Ang J; Temple G; Bell S; Shahidi M; Uttenreuther-Fischer M; Stopfer P; Futreal A; Calvert H; de Bono JS; Plummer R
J Clin Oncol; 2010 Sep; 28(25):3965-72. PubMed ID: 20679611
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2
Moulder SL; Borges VF; Baetz T; Mcspadden T; Fernetich G; Murthy RK; Chavira R; Guthrie K; Barrett E; Chia SK
Clin Cancer Res; 2017 Jul; 23(14):3529-3536. PubMed ID: 28053022
[No Abstract] [Full Text] [Related]
10. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
12. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH; Lee KH; Sohn JH; Lee KS; Jung KH; Kim JH; Lee KH; Ahn JS; Kim TY; Kim GM; Park IH; Kim SB; Kim SH; Han HS; Im YH; Ahn JH; Kim JY; Kang J; Im SA
Int J Cancer; 2018 Dec; 143(12):3240-3247. PubMed ID: 29978467
[TBL] [Abstract][Full Text] [Related]
15. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Das M; Padda SK; Frymoyer A; Molina J; Adjei A; Lensing JL; Miles D; Sikic BI; Wakelee HA
Cancer Chemother Pharmacol; 2018 Sep; 82(3):541-550. PubMed ID: 30030583
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
[TBL] [Abstract][Full Text] [Related]
17. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
[TBL] [Abstract][Full Text] [Related]
18. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Eskens FA; Mom CH; Planting AS; Gietema JA; Amelsberg A; Huisman H; van Doorn L; Burger H; Stopfer P; Verweij J; de Vries EG
Br J Cancer; 2008 Jan; 98(1):80-5. PubMed ID: 18026190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
